All In Biotech

Free tool

FAERS Monitor: Symdeko (Copackaged)

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210491 or its brand name (Symdeko (Copackaged), Ivacaftor, Ivacaftor, Tezacaftor). Reports on generic versions are filed under their own applications.

Reports

5,288

Serious

3,301

62% of reports

Hospitalization

2,899

Death reported

74

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • infective pulmonary exacerbation of cystic fibrosis1,183
  • hospitalisation459
  • infection352
  • cystic fibrosis288
  • pneumonia286
  • headache214
  • cough183
  • cystic fibrosis respiratory infection suppression168
  • pulmonary function test decreased144
  • nausea140
  • dyspnoea135
  • haemoptysis132
  • malaise113
  • fatigue102
  • nasopharyngitis100

Reports by year received

View as table
YearReports
20181,201
20193,045
2020801
202188
202238
202339
202439
202529
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,871 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infective pulmonary exacerbation of cystic fibrosisSignal1,1831104.11041.41,020,064
cystic fibrosis respiratory infection suppressionSignal168922.4781.6124,792
cystic fibrosisSignal288218.2194.458,839
pulmonary function test decreasedSignal144135.3114.818,433
haemoptysisSignal13218.916.02,214
hospitalisationSignal45911.910.94,598
infectionSignal3529.78.82,748
pneumoniaSignal2863.53.1520
coughSignal1832.62.3180
nasopharyngitisSignal1002.21.862
headache2141.41.220
malaise1131.00.90
dyspnoea1350.90.80
nausea1400.70.618
fatigue1020.50.446

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.